| 1 | Valuing health-related quality of life: An EQ-5D-5L value set for England | Health Economics (United Kingdom) | 2018 | 1,095 |
| 2 | EQ-5D and the EuroQol Group: Past, Present and Future | Applied Health Economics and Health Policy | 2017 | 963 |
| 3 | Development of the EQ-5D-Y: a child-friendly version of the EQ-5D | Quality of Life Research | 2010 | 723 |
| 4 | Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force | Value in Health | 2016 | 550 |
| 5 | A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol | Value in Health | 2014 | 398 |
| 6 | Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study | Quality of Life Research | 2010 | 391 |
| 7 | Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force | Value in Health | 2016 | 386 |
| 8 | Delivering precision oncology to patients with cancer | Nature Medicine | 2022 | 299 |
| 9 | Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force | Value in Health | 2013 | 273 |
| 10 | How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice | Health Research Policy and Systems | 2015 | 268 |
| 11 | Assessing the performance of the EQ-VAS in the NHS PROMs programme | Quality of Life Research | 2013 | 252 |
| 12 | Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines | European Journal of Health Economics | 2020 | 249 |
| 13 | Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data | Health Economics (United Kingdom) | 2010 | 235 |
| 14 | Why has therapy development for dementia failed in the last two decades? | Alzheimer's and Dementia | 2016 | 228 |
| 15 | The development of new research methods for the valuation of EQ-5D-5L | European Journal of Health Economics | 2013 | 224 |
| 16 | (null) | International Journal of Health Care Finance and Economics | 2003 | 223 |
| 17 | EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes | Pharmacoeconomics | 2016 | 219 |
| 18 | The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions | Health Economics (United Kingdom) | 2015 | 190 |
| 19 | Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards | Lancet Oncology, The | 2016 | 180 |
| 20 | Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report | Value in Health | 2012 | 168 |
| 21 | Severity of illness and priority setting in healthcare: A review of the literature | Health Policy | 2009 | 161 |
| 22 | Has payment by results affected the way that English hospitals provide care? Difference-in-differences analysis | BMJ: British Medical Journal | 2009 | 155 |
| 23 | Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force | Value in Health | 2020 | 155 |
| 24 | Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare? | Health and Quality of Life Outcomes | 2015 | 148 |
| 25 | A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7] | Value in Health | 2018 | 135 |
| 26 | Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward | Value in Health | 2019 | 134 |
| 27 | International Valuation Protocol for the EQ-5D-Y-3L | Pharmacoeconomics | 2020 | 131 |
| 28 | Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group | Value in Health | 2012 | 128 |
| 29 | A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach | Health Economics (United Kingdom) | 2011 | 123 |
| 30 | Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force | Value in Health | 2020 | 108 |
| 31 | Canʼt Get No Satisfaction? Will Pay for Performance Help? | Pharmacoeconomics | 2012 | 106 |
| 32 | Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare | European Journal of Health Economics | 2018 | 106 |
| 33 | Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L | Pharmacoeconomics | 2018 | 101 |
| 34 | Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective | Value in Health | 2018 | 100 |
| 35 | A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines | Value in Health | 2013 | 96 |
| 36 | Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom | BMC Medicine | 2016 | 96 |
| 37 | Gene therapy: evidence, value and affordability in the US health care system | Journal of Comparative Effectiveness Research | 2018 | 96 |
| 38 | Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis | Value in Health | 2017 | 95 |
| 39 | Learning from Thailand's health reforms | BMJ: British Medical Journal | 2004 | 93 |
| 40 | Operationalizing Value-Based Pricing of Medicines | Pharmacoeconomics | 2012 | 90 |
| 41 | EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories | Quality of Life Research | 2019 | 90 |
| 42 | Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context | Health Economics (United Kingdom) | 2015 | 89 |
| 43 | Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review | Lancet Oncology, The | 2018 | 86 |
| 44 | Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets | Pharmacoeconomics | 2018 | 85 |
| 45 | Using QALYs in Cancer | Pharmacoeconomics | 2012 | 82 |
| 46 | Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation | Health Policy | 2017 | 81 |
| 47 | Should NICE's threshold range for cost per QALY be raised? Yes | BMJ: British Medical Journal | 2009 | 79 |
| 48 | Real-world evidence for coverage decisions: opportunities and challenges | Journal of Comparative Effectiveness Research | 2018 | 77 |
| 49 | Valuing health at the end of life: A stated preference discrete choice experiment | Social Science and Medicine | 2015 | 75 |
| 50 | The Effect of Perceived Risks on the Demand for Vaccination: Results from a Discrete Choice Experiment | PLoS ONE | 2013 | 74 |
